Asahi Kasei Bioprocess will unveil its VANTIJ® SU-VFC benchtop at Bioprocess International (BPI) East in Boston this week. This new small-format system is designed to deliver automated, single-use virus filtration for laboratory-scale and process development applications. The system will be available on site at Booth 606.
The instrument is the first benchtop-scale platform in Asahi Kasei Bioprocess’s VANTIJ family. The system extends the automation and operator-focused design principles of the existing portfolio while simplifying virus filtration processes, according to the company.
Its design accommodates workflows using 0.12 m² or 0.3 m² Planova™ 35N virus-removal filters. The VANTIJ simplifies small-scale Planova virus filtration while maintaining the process control and data-focused capabilities expected in biopharmaceutical development, explains an Asahi spokesperson.
Initially designed for gene therapy manufacturing, the new benchtop helps address the operational complexities associated with long production timelines, regulatory requirements, operator training, and therapy-specific needs, continues the company official, who adds that the system offers clear setup through a guided shadow-board layout, tool-free tube set installation and replacement, intuitive connection points, and recipe-driven software. It also enables batch reporting and supports the execution of key filtration processes.
“The biopharmaceutical industry continues to pursue more efficient pathways for bringing innovative therapies to patients,” said Chris Rombach, president of Asahi Kasei Bioprocess America. “The VANTIJ SU-VFC Benchtop reflects Asahi Kasei Bioprocess’s commitment to supporting manufacturers with solutions that simplify critical process steps.”
Rombach explains that the fluid management business unit of Asahi Kasei Bioprocess focuses on solving therapeutic product safety, efficiency, and purity challenges within the pharmaceutical and bioprocessing industries. With technology platforms for virus filtration, chromatography, inline buffer formulation and oligonucleotide synthesis, the company’s bioprocessing systems, columns, and automation solutions advance GMP manufacturing of critical drug substances around the world, he continued.
BPI East attendees can visit Booth 606 in Boston from September 22nd to 25th.
Facts Only
* Asahi Kasei Bioprocess will unveil its VANTIJ® SU-VFC benchtop at Bioprocess International (BPI) East in Boston.
* The system is designed for automated, single-use virus filtration for laboratory-scale and process development.
* The instrument is the first benchtop-scale platform in Asahi Kasei Bioprocess’s VANTIJ family.
* The system accommodates workflows using $0.12 \text{ m}^2$ or $0.3 \text{ m}^2$ Planova™ 35N virus-removal filters.
* The benchtop aims to simplify small-scale Planova virus filtration while maintaining process control and data capabilities.
* The system addresses operational complexities related to gene therapy manufacturing, including production timelines, regulatory requirements, operator training, and therapy-specific needs.
* The system features a guided shadow-board layout for setup and tool-free tube set installation/replacement.
* It includes intuitive connection points and recipe-driven software to enable batch reporting and filtration execution.
* Chris Rombach, president of Asahi Kasei Bioprocess America, stated the VANTIJ reflects a commitment to supporting manufacturers with solutions that simplify critical process steps.
Executive Summary
Asahi Kasei Bioprocess will present its VANTIJ® SU-VFC benchtop system at Bioprocess International (BPI) East in Boston, where it will be available at Booth 606 from September 22nd to 25th. This new small-format system is designed to provide automated, single-use virus filtration for laboratory-scale and process development applications. The VANTIJ family represents the first benchtop-scale platform in Asahi Kasei Bioprocess’s portfolio, aiming to simplify virus filtration processes while retaining the automation and operator-focused design principles of existing systems.
The system accommodates workflows using Planova™ 35N virus-removal filters, allowing for setups with either $0.12 \text{ m}^2$ or $0.3 \text{ m}^2$. The VANTIJ aims to simplify small-scale filtration while maintaining the process control and data capabilities essential in biopharmaceutical development. Initially targeted for gene therapy manufacturing, the benchtop addresses complexities like long timelines, regulatory needs, operator training, and therapy-specific demands. The system incorporates features such as a guided shadow-board layout for setup, tool-free filter installation, intuitive connections, and recipe-driven software to facilitate batch reporting and key filtration processes.
Full Take
The narrative positions the VANTIJ SU-VFC as a solution to the friction inherent in scaling biopharmaceutical processes—specifically addressing the operational complexities of long timelines, regulatory overhead, and specialized training required for gene therapy manufacturing. The pattern observed is the framing of technical innovation not just as an engineering advancement, but as a direct mechanism for reducing operational burden ("simplify critical process steps"). This shifts the focus from the physical mechanics of filtration to the administrative and human costs associated with production complexity.
The emphasis on "automation" and "operator-focused design" acts as a bridge between high-level scientific goals (therapy delivery) and practical execution, suggesting that successful innovation in this sector requires simplifying the 'middle layer' of process management. The integration of software-driven features like recipe guidance and batch reporting reflects a systemic need to impose structure on inherently variable biological processes. The implicit implication is that efficiency is not merely about faster filtration rates but about reducing human error potential and regulatory compliance risk across multi-stage workflows.
The underlying assumption is that complexity is an obstacle to therapeutic advancement, and technology's role is prescriptive: remove obstacles. This resonates with a broader pattern in high-tech industries where the perceived bottleneck shifts from raw capability to workflow integration. The question for observers is whether this focus on simplifying process steps addresses the deeper structural challenges within the biopharma ecosystem, or if it merely offers optimized tools for existing regulatory structures. What are the hidden costs associated with streamlining training and setup versus achieving efficiency targets in these highly regulated environments?